Michelle Neice
Internal Medicine · Douglas, WYNPI 1770926909
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 168 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$664
- Johnson & Johnson$593
- Boston Scientific$377
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$373
- Takeda Pharmaceuticals U.S.A., Inc.$310
- Janssen Scientific Affairs, LLC$260
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,399100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $664 |
| Johnson & Johnson | 22 | $593 |
| Boston Scientific | 4 | $377 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $310 |
| Janssen Scientific Affairs, LLC | 3 | $260 |
| Fujifilm Healthcare Americas Corporation | 2 | $250 |
| Regeneron Healthcare Solutions, Inc. | 4 | $194 |
| AstraZeneca | 12 | $185 |
| ERBE USA Inc | 2 | $175 |
| GSK | 10 | $169 |
| Phathom Pharmaceuticals, Inc. | 2 | $135 |
| Amgen | 9 | $114 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Lilly USA, LLC | 5 | $61 |
| Daiichi Sankyo Inc. | 4 | $58 |
| Gilead | 2 | $51 |
| Merck | 3 | $48 |
| Pfizer | 3 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $35 |
| Novo Nordisk | 2 | $29 |
| Sanofi | 1 | $28 |
| Organon | 2 | $28 |
| Novartis | 2 | $27 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Optinose US, Inc. | 1 | $17 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$277
- uTASWako AFP-L3$250
- Tremfya$150
- X-Tack Endoscopic HeliX Tacking System$126
- XIFAXAN$125
- VOQUEZNA$112
- VIO3$100
How this compares
$4,399 in reported general payments places this provider in the 95th percentile of 101 internal medicine providers in Wyoming.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 27 | $829,929 |
| RinvoqUpadacitinib | 13 | $88,988 |
| XifaxanRifaximin | 14 | $42,069 |
| VemlidyTenofovir Alafenamide | 24 | $33,845 |
| LinzessLinaclotide | 20 | $12,776 |
| Pantoprazole Sodium | 49 | $463 |
| Omeprazole | 40 | $362 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 16 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $593 | $829,92927 claims |
| AbbVieRinvoq, Linzess | $664 | $101,76433 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $373 | $42,06914 claims |
| GileadVemlidy | $51 | $33,84524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 internal medicine providers in Wyoming.
Other internal medicine in Douglas
- John ThalkenDouglas$1K
- Israel StewartRock Springs$6K
- David WalkerSheridan$3K
- Juli AckermanSheridan$3K
- Hannah HallSheridan$3K
- Kristopher SchamberSheridan$2K
- Julie CarlsonLaramie$2K
- Derek RedingerSheridan$1K
- Terry DonaldsonRock Springs$1K
- Erin HendersonSheridan$991
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.